Abstract:Background CD4+CD25+Foxp3+ T regulatory (Treg) cells play a key role in peripheral tolerance. Rapamycin was approved by the FDA to preserve renal allografts and to be efficacious in patients with several autoimmune diseases [1]. Objectives To investigate the status of Treg cells in active refractory rheumatoid arthritis (RA) and the effects of rapamycin on patients with RA. Methods Forty-five active refractory RA patients were enrolled. Rapamycin was used at a dose of 0.5 mg every 2 days [the preliminary, open-label clinical trial of rapamycin (Clinical Trials.gov number: ChiCTR-IPR-17010307)]. Clinical improvement and immunological assessments were performed before 1st rapamycin dose and 12 weeks post treatment. Blood samples were obtained from RA patients and 75 healthy volunteers for estimation of CD4+ T cell subsets. Results Two patients dropped out due to non-compliance. As compared to healthy controls (median of Treg cells: 33.32 cell/ul), the absolute counts of circulating Treg cells were significantly decreased in patients with active refractory RA (median: 27.17 cell/ul; P=0.046). While the median ratios of Th17/Treg cells in patients with active refractory RA (median: 0.26) were significantly higher than those of healthy volunteers (median: 0.19; P=0.029). No difference in the absolute counts of circulating Th17 cells and Th1 cells was observed between patients with active refractory RA and healthy subjects. Rapamycin treatment led to clinical improvement with the median post-treatment DAS28-ESR decreasing when compared to baseline (from 4.19 to 3.78) in active refractory RA patients. Sixteen patients (16/43 patients, 37.21%) achieved an EULAR moderate response and 6 patients (6/43 patients, 13.95%) reached good response at week 12. Rapamycin administration resulted in an increase in the absolute counts of Treg cells in active refractory RA patients, from a median of 27.17 cell/ul (at week 0) to 37.57 cell/ul (at week 12) (P=0.041). The ratios of Th17/Treg cells shows a reduction from a median of 0.26 at baseline to 0.20 at week 12, but the difference is not significant (P =0.376). No significant difference was observed in the absolute counts of circulating Th17 and Th1 cells after rapamycin treatment. Interestingly, we observed that Treg cells increased before the complete remission of the disease (DAS28 score <2.6) in patients with active refractory RA. At week 12, the mean dose of prednisone which refractory RA patients were receiving decreased from 11.98 mg/d to 8.31 mg/d, with a dose reduced by ≥30% than that at baseline. The categories of DMARDs use were also reduced (P<0.05). No serious adverse events was observed during the 12-week period of rapamycin treatment. Conclusions Reduced absolute number of Treg cells was found in the patients with active refractory RA, indicating an imbalance between Th17 and Treg cells. Rapamycin elicits rapid improvement of disease activity via restoring circulating Treg cells numbers in patients with active refractory RA. References Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016. 12(3): 169–82. Disclosure of Interest None declared

Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis

Targeted Drug Delivery Strategies for the Treatment of Rheumatoid Arthritis

FRI0063 Rapamycin Induces Remission in Patients with Refractory Rheumatoid Arthritis

Epidermal growth factor receptor (EGFR) as a therapeutic target in rheumatoid arthritis

The mammalian target of rapamycin contributes to synovial fibroblast pathogenicity in rheumatoid arthritis

THU0176 Efficiency and safety of rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis

Sphingosine-1-phosphate: a Potential Therapeutic Target for Rheumatoid Arthritis

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

AB0376 Rapamycin induces remission in patients with newly diagnosed rheumatoid arthritis

Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis

Targeting Pathways and Integrated Approaches to Treat Rheumatoid Arthritis

Rapamycin regulates osteogenic differentiation through Parkin-mediated mitophagy in rheumatoid arthritis

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

mTOR Regulates the Invasive Properties of Synovial Fibroblasts in Rheumatoid Arthritis

AB0421 Rapamycin Reduces Disease Activity Through Restoring Regulatory T Cell Numbers in Patients with Active Refractory Rheumatoid Arthritis

G-Protein-Coupled Receptors in Rheumatoid Arthritis: Recent Insights into Mechanisms and Functional Roles

Rheumatoid arthritis: pathogenesis and therapeutic advances

New molecular targets in the treatment of rheumatoid arthritis

Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review

Exploring the therapeutic potential of regulatory T cell in rheumatoid arthritis: Insights into subsets, markers, and signaling pathways

Immuno-metabolic reprogramming of T cell: a new frontier for pharmacotherapy of Rheumatoid arthritis